Cover Image

RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab

Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent. However, some clinical situations do not allow application of tumouricidal doses (i.e. re-irradiation) hence radiation sensitization by exploitation of high endothelial growth factor receptor (EGFR)-...

Full description

Saved in:
Bibliographic Details
Main Authors: Jensen, Alexandra (Author) , Krauß, Jürgen (Author) , Weichert, Wilko (Author) , Debus, Jürgen (Author) , Münter, Marc (Author)
Format: Article (Journal)
Language:English
Published: 03 November 2010
In: Radiation oncology
Year: 2010, Volume: 5, Pages: 1-8
ISSN:1748-717X
DOI:10.1186/1748-717X-5-102
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1748-717X-5-102
Get full text
Author Notes:Alexandra D. Jensen, Jürgen Krauss, Wilko Weichert, Jürgen Debus, Marc W. Münter
Description
Summary:Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent. However, some clinical situations do not allow application of tumouricidal doses (i.e. re-irradiation) hence radiation sensitization by exploitation of high endothelial growth factor receptor (EGFR)-expression in ACC seems beneficial. This is a single-institution experience of combined radioimmunotherapy (RIT) with the EGFR-inhibitor cetuximab.
Item Description:Gesehen am 24.08.2023
Physical Description:Online Resource
ISSN:1748-717X
DOI:10.1186/1748-717X-5-102

Similar Items